Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib

Autor: Lisbeth Enggaard, Emelie Curovic Rotbain, Rasmus Heje Thomsen, Mikael Frederiksen, Robert Schou Pedersen, Michael Asger Andersen, Tine Bjørn Nielsen, Ilse Christiansen, Olav J. Bergmann, Carsten Utoft Niemann, Henrik Frederiksen, Kathrine Aarup

Publikováno v: Aarup, K, Rotbain, E C, Enggaard, L, Pedersen, R S, Bergmann, O J, Thomsen, R H, Frederiksen, M, Frederiksen, H, Nielsen, T, Christiansen, I, Andersen, M A & Niemann, C U 2020, ' Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib ', European Journal of Haematology, vol. 105, no. 5, pp. 646-654 . https://doi.org/10.1111/ejh.13499
Aarup, K, Rotbain, E C, Enggaard, L, Pedersen, R S, Bergmann, O J, Thomsen, R H, Frederiksen, M, Frederiksen, H, Nielsen, T, Christiansen, I, Andersen, M A & Niemann, C U 2020, ' Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib ', European journal of haematology, vol. 105, no. 5, pp. 646-654 . https://doi.org/10.1111/ejh.13499

Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860aa20e080b8747baf043fb2631f964
https://pubmed.ncbi.nlm.nih.gov/32736410

Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

Autor: Rasmus Heje Thomsen, Jette Sønderskov Gørløv, Søren Ramme Nielsen, Charlotte Madsen, Susanne Oksbjerg Dalton, Kristina Fruerlund Nielsen, Peter de Nully Brown, Maja Halgren Olsen, Bente Arboe, Anne Katrine Duun-Henriksen

Publikováno v: Arboe, B, Halgren Olsen, M, Duun-Henriksen, A K, Gørløv, J S, Nielsen, K F, Thomsen, R H, Madsen, C, Ramme Nielsen, S, Dalton, S O & Brown, P D N 2018, ' Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation ', Leukemia and Lymphoma, vol. 59, no. 5, pp. 1153-1162 . https://doi.org/10.1080/10428194.2017.1369061
Arboe, B, Halgren Olsen, M, Duun-Henriksen, A K, Gørløv, J S, Nielsen, K F, Thomsen, R H, Madsen, C, Nielsen, S R, Dalton, S O & Brown, P D N 2018, ' Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation ', Leukemia and Lymphoma, vol. 59, no. 5, pp. 1153-1162 . https://doi.org/10.1080/10428194.2017.1369061

In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing AS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1740139ca7428f6006413c145c81abc
https://portal.findresearcher.sdu.dk/da/publications/1af97bf7-5eb6-4557-a706-f2b00777ae55

Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in Denmark 2000-2012

Autor: Peter de Nully Brown, Charlotte Madsen, Kristina Fruerlund Nielsen, Rasmus Heje Thomsen, Bente Arboe, Jette Soenderskov Goerloev, Soeren Ramme Nielsen

Publikováno v: Arboe, B, Fruerlund Nielsen, K, Madsen, C, Thomsen, R H, Ramme Nielsen, S, Gørløv, J S & de Nully Brown, P 2015, ' Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in Denmark 2000-2012 ', Blood, vol. 126, no. 23, pp. 1983 . < http://www.bloodjournal.org/content/126/23/1983 >

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the largest subgroup of malignant lymphoma. Today more than 80% of the patients will achieve partial or complete remission. However more than 20 % will either relapse or present with refractory d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9689b843aafe134ca86692374d6fad19
https://vbn.aau.dk/da/publications/f8446c0e-0e9c-4c97-9cec-c75976ad0e33